社区获得性肺炎预后评价的研究进展

Research Advances in the Prognostic Assessment of Community-acquired Pneumonia

社区获得性肺炎(CAP)目前仍然具有较高的发病率和病死率,严重威胁人类健康,造成社会和经济的损失。CAP严重程度分级对判断患者选择恰当的治疗场所及合理的抗生素治疗有重要意义,是CAP诊治的基础。基于30 d病死率的肺炎评分系统,目前用于判断患者危险度。然而,每个肺炎评分系统对各个危险层面的患者反映出不同的敏感性和特异性,各自仍存在其局限性。目前许多研究转向针对CAP严重程度的特异性标志物,如细菌的基因载量。

Community-acquired pneumonia （CAP） remains in high morbidity and mortality, which greatly threatens people＇s health and leads to great loss of social and economic resources. The severity assessment of CAP has great importance in the selection of the most appropriate site of medical care and antibiotic therapy,which is the basis of the diagnosis and treatment for the disease. Several clinical scoring systems based on 30-day mortality have been developed to assess on the severity of CAP among patients with the highest risk of death. However,each system has its own limitations and different sensitivity and specificity. Therefore, current research has focused on the use of specific biomarkers to predict CAP severity, such as bacterial genomic load quantification.